Results 41 to 50 of about 4,368 (233)
Journal of Neuroendocrinology, Volume 35, Issue 8, August 2023., 2023 Abstract This ENETS guidance paper aims to provide practical advice to clinicians for the diagnosis, treatment and follow‐up of functioning syndromes in pancreatic neuroendocrine tumours (NET). A NET‐associated functioning syndrome is defined by the presence of a clinical syndrome combined with biochemical evidence of inappropriately elevated hormonal ...
Johannes Hofland +35 more
wiley +1 more source
F1000Research, 2017 Background: Growth hormone (GH) is known to affect insulin and glucose metabolism. Blocking its effects in acromegalic patients improves diabetes and glucose metabolism.
Ada P. Lee +4 more
doaj +1 more source
Resistance to drug treatment of acromegaly and ways to overcome it
Ожирение и метаболизм, 2021 Acromegaly is a severe disabling neuroendocrine disease caused by hypersecretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). The problem of resistance to drug therapy in patients with acromegaly is quite common in clinical practice ...
O. O. Golounina +3 more
doaj +1 more source
Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance [PDF]
, 2001 The roles of GH and its receptor (GHR) in metabolic control are not yet fully understood. We studied the roles of GH and the GHR using the GHR antagonist pegvisomant for metabolic control of healthy nonobese men in ...
Bidlingmaier, M. (Martin) +6 more
core +1 more source
Archives of Endocrinology and Metabolism, 2016 Objective To describe the safety and efficacy of pegvisomant therapy and the predictors of treatment response in acromegaly patients at a single tertiary reference center in Brazil.
Leandro Kasuki +7 more
doaj +1 more source
A male patient with acromegaly and breast cancer: treating acromegaly to control tumor progression [PDF]
, 2015 BACKGROUND: Acromegaly is a rare disease associated with an increased risk of developing cancer. CASE PRESENTATION: We report the case of a 72-year-old man who was diagnosed with acromegaly (IGF-1 770 ng/ml) and breast cancer.
Alberto Zambelli +7 more
core +1 more source
ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs
Endocrine-Related CancerMarta Araujo‐Castro +46 more
openalex +2 more sources
Cost-effectiveness analysis of preoperative treatment of acromegaly with somatostatin analogue on surgical outcome [PDF]
, 2015 [Abstract] Context. There is no uniform standard of care for acromegaly. Due to the high costs involved, steps must be taken to ensure the cost-effective delivery of treatment. Objective.
Cordido, Fernando +7 more
core +2 more sources
Bagcilar Medical Bulletin, 2022 McCune-Albright syndrome constitutes of fibrous dysplasia, café-au-lait macules, and various endocrinopathies such as thyroid, cortisol, prolactin and growth hormone hypersecretion.
Hande Peynirci, Onur Elbasan
doaj +1 more source
Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant [PDF]
, 2016 Background: Growth hormone secreting pituitary adenomas (somatotroph adenoma) predominantly express somatostatin receptors (SSTRs) subtypes 2 and 5. Higher SSTR2 expression on somatotroph adenomas results in a better response to somatostatin analogues ...
Dallenga, A.H.G. +7 more
core +1 more source